Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Asian Market Preview: Nikkei Futures (0.49%), Hang Seng Futures 0.00%, ASX SPI 200 0.00%, S&P Futures (0.47%)

Apr 20 ,2025

  • Synopsis:

    • Asian markets set for cautious start to Monday trade with futures signaling opening declines in Japan. Thin volume session ahead with Hong Kong and Australia among markets closed for Easter Monday holiday. S&P 500 futures weakening after major US indexes capped off weekly loss. Dollar seeing mild declines after falling to early 2022 lows last week. Crude under some pressure while gold hitting fresh record high. Bitcoin flat.

    • Weekend press on tariffs mostly discussed fallout from chill in US-China trade (Ford suspending shipments, Boeing returning jet, China halting LNG purchases). On Thursday Trump ruled out further China tariff hikes while signaling openness for lower rates and revealing both sides are engaged in talks (though Reuters sources added nothing high level). China's US ambassador also urged de-escalation while repeating preparedness to fight. Tensions have risen beyond tariffs with Washington tightening chip export controls and imposing steep port fees on Chinese vessels.

    • China expected to leave 1Y and 5Y loan prime rates unchanged Monday. Policy easing expectations have strengthened in wake of US-China tariff war with economists eyeing further RRR and rate cuts. However, yuan depreciation and low bank interest margins seen as constraints to near-term easing. On fiscal policy front, sell-side firms anticipate Beijing to speed up NPC stimulus rollout while some see scope for authorities to raise fiscal deficit ratio amid thoughts existing measures not enough to fully offset tariff impact.

    • In other trade news, South Korea to send top trade official to Washington for talks with US, coming after Japan opened negotiations last week. Nikkei reported Japan may review auto safety rules as part of US trade talks, following complaints by US automakers about onerous standards. In other developments, Taiwan to extend short-selling ban without giving expected end date. China proposed easing foreign equity ratio caps as part of efforts to open up services sector.

    • China LPR decision headlines quiet Monday before IMF World Economic Outlook on Tuesday expected to show downgrade to global growth forecasts, and upgrade to inflation projections Global flash PMIs (Wed) will offer early read on impact on manufacturers this month from tariffs. Tokyo CPI (Fri), Japan corporate services inflation (Thurs), and South Korea Q1 GDP (Thurs) also due out. Busy week of Fedspeak with policymakers having stuck to their patience mantra.

  • Pre-open Company News:

    • 532523.IN -- Biocon to consider fundraising plan at 23-Apr meeting

    • 600584.CH -- JCET Group confirms FY results as reported 8-Apr

    • 600392.CH -- Shenghe Resources says MP Materials's cessation of rare earth concentrate shipments to China will not have major impact on company

    • 688276.CH -- Changchun BCHT Biotechnology confirms FY preliminary results, as reported on 25-Feb

    • 688276.CH -- Changchun BCHT Biotechnology releases sustainability report

    • 688276.CH -- Changchun BCHT Biotechnology reports Q1 net income attributable CNY1.1M vs year-ago CNY60.6M

    • 600584.CH -- JCET Group releases sustainability report

    • 600584.CH -- JCET Group's board proposes declaring interim dividend for 2025

    • 600276.CH -- NMPA approves phase Ib/II trial of combining Hengrui Pharmaceuticals's HRS-1167 with AA-P for prostate cancer

    • 600276.CH -- NMPA approves trial of Hengrui Pharmaceuticals's HRS-9813 for progressive pulmonary fibrosis

    • 300601.CH -- Shenzhen Kangtai Biological Products reports FY net income attributable CNY201.7M vs guidance CNY190.0-270.0M

    • 300601.CH -- Shenzhen Kangtai Biological Products releases sustainability report

    • 300601.CH -- Shenzhen Kangtai Biological Products reports Q1 net income attributable CNY22.4M vs year-ago CNY54.1M

    • 301219.CH -- Tengyuan Cobalt reports FY net income attributable CNY685.2M vs guidance CNY609.0-792.0M

    • 301219.CH -- Tengyuan Cobalt reports Q1 net income attributable CNY123.5M, (14%) vs year-ago CNY144.0M

  • On Deck:

    • China:

      • Economic:

        • 08:00 CST: Foreign Direct Investment Y/Y

        • 09:30 CST: 1 and 5 Year Loan Prime Rate; consensus no change

      • Earnings:

        • JCET Group (600584.CH), JCET Group (600584.CH)

    • Hong Kong:

      • Earnings:

        • Xinte Energy (1799.HK), Zhaojin Mining Industry (1818.HK)

    • India:

      • Earnings:

        • Tata Investment (501301.IN), Himadri Speciality Chemical (500184.IN), Alok Industries (521070.IN)

  • Market Data:

    • Gold (Jun 25): +$34.20 or +1.03% to $3362.60

    • WTI Crude (May 25): ($0.95) or (1.47%) to $63.73

    • $-¥: (0.88) or (0.62%) to 141.5610

    • $-KRW: (1.00) or (0.07%) to 1417.4000

    • A$-$: (0.00) or (0.06%) to 0.6387

    • $-INR: +0.04 or +0.05% to 85.4563

    • $-CNY: (0.00) or (0.01%) to 7.2993

  • If you would like to receive the Asian Market Preview daily, please search for Asia Pre-Market Updates in Alert Manager.

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE